Kineta Debt to Equity Ratio 2014-2024 | KANT
Current and historical debt to equity ratio values for Kineta (KANT) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Kineta debt/equity for the three months ending June 30, 2024 was 0.05.
| Kineta Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-06-30 |
$0.01B |
$-0.01B |
-1.18 |
| 2024-03-31 |
$0.01B |
$-0.01B |
-1.39 |
| 2023-12-31 |
$0.01B |
$0.00B |
2.36 |
| 2023-09-30 |
$0.01B |
$0.00B |
2.71 |
| 2023-06-30 |
$0.01B |
$0.01B |
1.30 |
| 2023-03-31 |
$0.01B |
$0.00B |
-234.04 |
| 2022-12-31 |
$0.01B |
$0.01B |
2.82 |
| 2022-09-30 |
$0.00B |
$0.01B |
0.75 |
| 2022-06-30 |
$0.01B |
$0.01B |
0.95 |
| 2022-03-31 |
$0.02B |
$0.01B |
1.70 |
| 2021-12-31 |
$0.03B |
$-0.01B |
-2.12 |
| 2021-09-30 |
$0.04B |
$0.03B |
1.15 |
| 2021-06-30 |
$0.04B |
$0.04B |
0.98 |
| 2021-03-31 |
$0.04B |
$0.05B |
0.89 |
| 2020-12-31 |
$0.06B |
$0.06B |
1.04 |
| 2020-09-30 |
$0.02B |
$0.04B |
0.47 |
| 2020-06-30 |
$0.02B |
$0.05B |
0.42 |
| 2020-03-31 |
$0.02B |
$0.05B |
0.38 |
| 2019-12-31 |
$0.02B |
$-0.00B |
-9.00 |
| 2019-09-30 |
$0.02B |
$0.07B |
0.34 |
| 2019-06-30 |
$0.02B |
$0.08B |
0.29 |
| 2019-03-31 |
$0.02B |
$0.10B |
0.22 |
| 2018-12-31 |
$0.02B |
$0.11B |
0.19 |
| 2018-09-30 |
$0.03B |
$0.04B |
0.64 |
| 2018-06-30 |
$0.02B |
$0.06B |
0.41 |
| 2018-03-31 |
$0.02B |
$0.06B |
0.37 |
| 2017-12-31 |
$0.01B |
$0.07B |
0.14 |
| 2017-09-30 |
$0.02B |
$0.04B |
0.58 |
| 2017-06-30 |
$0.01B |
$0.05B |
0.21 |
| 2017-03-31 |
$0.01B |
$0.07B |
0.13 |
| 2016-12-31 |
$0.01B |
$0.08B |
0.12 |
| 2016-09-30 |
$0.01B |
$0.09B |
0.15 |
| 2016-06-30 |
$0.01B |
$0.03B |
0.46 |
| 2016-03-31 |
$0.01B |
$0.04B |
0.31 |
| 2015-12-31 |
$0.02B |
$0.00B |
3.46 |
| 2015-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2015-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2015-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2014-12-31 |
$0.02B |
$-0.01B |
-2.43 |
| 2013-12-31 |
$0.01B |
$0.00B |
2.34 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
